Dr. Ornstein on Unmet Needs in Refractory RCC

In Partnership With:

Partner | Cancer Centers | <b>Cleveland Clinic</b>

Moshe Ornstein, MD, MA, discusses unmet needs in metastatic renal cell carcinoma.

Moshe Ornstein, MD, MA, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses unmet needs in metastatic renal cell carcinoma (mRCC).

Although there has been much progress over the past 5 to 10 years in the treatment of patients with metastatic kidney cancer, there are remaining questions that the field must address with future research and clinical trials, Ornstein says. Much of the progress has been in treatment-naïve mRCC, but how to manage those patients after their cancer progresses on front-line therapies remains a challenge, Ornstein explains.

Many of the agents that are available for refractory RCC have response rates between 20% and 30% and poor progression-free survival, Ornstein continues. Overall, trials are aiming to discover a therapy that can produce durable benefit in patients with refractory RCC, Ornstein concludes.